<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02702960</url>
  </required_header>
  <id_info>
    <org_study_id>J15171</org_study_id>
    <secondary_id>IRB00080373</secondary_id>
    <nct_id>NCT02702960</nct_id>
  </id_info>
  <brief_title>Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Fibrolamellar or Non-fibrolamellar Hepatocellular Carcinoma (HCC) Including Fibrolamellar HCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fibrolamellar Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a phase II, single arm, open-label, single center study to assess a&#xD;
      reduced-intensity conditioning regimen, bone marrow transplantation and high dose PTCy in&#xD;
      recipients of a partial liver allograft from a Human Leukocyte Antigen (HLA)-matched or&#xD;
      -haploidentical living related donor in patients with HCC.&#xD;
&#xD;
      The primary objective of this trial is to characterize recurrence-free survival at 1 year&#xD;
      following bone marrow transplantation among recipients of prior partial liver transplantation&#xD;
      from the same donor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to characterize the safety and anti-tumor efficacy of sequential&#xD;
      partial liver transplantation followed by bone marrow transplantation from the same living&#xD;
      related donor. This treatment applies to patients whose cancer remains confined to the liver&#xD;
      but is too widespread to be removed by surgery or treated by a liver transplant from a&#xD;
      deceased donor. The purpose of this combined treatment is to reduce the risk of the cancer&#xD;
      coming back after the liver transplant The bone marrow transplant may reduce the risk of&#xD;
      cancer relapse in two ways. First, patients who have combined bone marrow and solid organ&#xD;
      transplants may be able to get off all anti-rejection drugs, which inhibit the immune system&#xD;
      from destroying cancer cells. Second, the donor's bone marrow contains cells of the immune&#xD;
      system, which can attack any cancer cells that remain after the liver transplant.&#xD;
&#xD;
      This trial is a phase II, single arm, open-label, single center pilot study to assess a&#xD;
      reduced-intensity conditioning regimen, bone marrow transplantation and high dose&#xD;
      post-transplantation cyclophosphamide (PTCy) in recipients of a partial liver allograft from&#xD;
      a Human Leukocyte Antigen (HLA)-matched or -haploidentical living related donor in patients&#xD;
      with HCC. The trial includes analyses of tumor characteristics and the number and phenotype&#xD;
      of tumor infiltrating lymphocytes in the explanted tumor. The trial also includes periodic&#xD;
      monitoring of circulating hepatocytes to correlate with tumor response.&#xD;
&#xD;
      The study is expected to take two years to complete accrual of six patients, and the primary&#xD;
      objective of this trial is to characterize recurrence-free survival at 1 year following bone&#xD;
      marrow transplantation among recipients of prior partial liver transplantation from the same&#xD;
      donor. Secondary objectives include documenting percentage of patients who become tolerant of&#xD;
      the transplanted liver, i.e. off immunosuppression for &gt;6 months without biochemical evidence&#xD;
      of liver rejection, and characterizing the relationship between donor chimerism and&#xD;
      transplantation tolerance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    This study was withdrawn due to lack of necessary resources from the liver transplant surgical&#xD;
    group.&#xD;
  </why_stopped>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">January 3, 2018</completion_date>
  <primary_completion_date type="Actual">January 3, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1 year disease-free survival (at 1 year after BMT)</measure>
    <time_frame>1 year</time_frame>
    <description>Disease-free is defined as the lack of radiographic evidence of recurrence by computed tomography or MRI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Graft versus Host Disease</measure>
    <time_frame>1 year</time_frame>
    <description>Determine the cumulative incidences of acute grades II-IV, III-IV and chronic graft-versus-host disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of transplanted participants who die</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver allograft failure</measure>
    <time_frame>1 year</time_frame>
    <description>Determine the proportion of transplanted participants with liver allograft rejection demonstrated by a biopsy or clinically if a biopsy cannot be performed.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Efficacy measure - proportion disease free</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of transplanted participants who remain free of disease recurrence for 1 year post bone marrow transplantation</description>
  </other_outcome>
  <other_outcome>
    <measure>Efficacy measure- proportion off immunosuppression without graft versus host disease (GVHD) or liver rejection</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of participants who are off immunosuppression without GVHD or liver rejection at 1 year after bone marrow transplantation.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Fibrolamellar Hepatocellular Carcinoma</condition>
  <condition>Hepatocellular Carcinoma (Fibrolamellar Variant)</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>part. liver transplant and BMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive living related donor partial liver transplantation performed according to standard practices. Patients will be maintained on tacrolimus, MMF, and prednisone after liver transplantation.&#xD;
Upon recovery, patient must undergo eligibility screening for bone marrow transplantation (BMT).&#xD;
If eligible, patients will begin:&#xD;
Antithymocyte globulin (ATG): Day -16 to Day -14; fludarabine: Days -6 to Day -2 low-dose cyclophosphamide: Day -6 and -5. Tacrolimus, mycophenolate mofetil (MMF), and prednisone: day -7 and day -6. Total body irradiation on Day -1 Bone marrow infusion on Day 0. High dose cyclophosphamide plus MESNA: Day 3 and 4th Filgrastim, tacrolimus,MMF, and prednisone: Day 5 until neutrophil counts recover.&#xD;
Patients followed up through post transplant day 60, then weekly following discharge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>living related donor partial liver transplantation</intervention_name>
    <description>HLA matched or haploidentical related living donor partial liver transplant followed by tacrolimus, prednisone, and MMF immunosuppression for &gt;3 wks</description>
    <arm_group_label>part. liver transplant and BMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total body irradiation</intervention_name>
    <description>200 cGy total body irradiation (TBI) on Day -1.</description>
    <arm_group_label>part. liver transplant and BMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow transplant from same donor</intervention_name>
    <description>BMT using cells from the same Human Leukocyte Antigen (HLA)-matched or -haploidentical living related donor will be performed on Day 0</description>
    <arm_group_label>part. liver transplant and BMT</arm_group_label>
    <other_name>BMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Pre-transplantation low dose cyclophosphamide given day -6 and -5 Post-transplantation high dose cyclophosphamide (PTCy; 50 mg/kg/day) will be administered on Days 3 and 4 with hydration</description>
    <arm_group_label>part. liver transplant and BMT</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>administered on Days 3 and 4 with PTCy</description>
    <arm_group_label>part. liver transplant and BMT</arm_group_label>
    <other_name>sodium-2-mercaptoethane sulfonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>administered daily starting on Day 5 until absolute neutrophil count (ANC) recovery</description>
    <arm_group_label>part. liver transplant and BMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT</description>
    <arm_group_label>part. liver transplant and BMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT</description>
    <arm_group_label>part. liver transplant and BMT</arm_group_label>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT</description>
    <arm_group_label>part. liver transplant and BMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithymocyte globulin</intervention_name>
    <description>Given from Day -16 to Day -14 prior to bone marrow transplantation on day 0</description>
    <arm_group_label>part. liver transplant and BMT</arm_group_label>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine</intervention_name>
    <description>fludarabine given from Days -6 to Day -2 before BMT</description>
    <arm_group_label>part. liver transplant and BMT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        RECIPIENT&#xD;
&#xD;
          1. Histologic diagnosis of liver-confined fibrolamellar or non-fibrolamellar HCC.&#xD;
             Ineligible for curative resection or deceased donor liver transplantation by virtue of&#xD;
             NOT meeting the Milan criteria or down-staging criteria:&#xD;
&#xD;
               1. Single viable tumor ≤5 cm in size or ≤3 tumors each ≤3 cm in size based on CT or&#xD;
                  Magnetic resonance (MR) imaging&#xD;
&#xD;
               2. Pretransplant alpha fetoprotein (AFP) level of ≤400.&#xD;
&#xD;
          2. Available human leukocyte antigen (HLA)-matched or -haploidentical, living related&#xD;
             donor who is willing to donate bone marrow and part of liver. The donor and recipient&#xD;
             must be HLA identical for at least one allele (using high resolution DNA based typing)&#xD;
             at the following genetic loci: HLA-A, HLA-B, HLA-C and HLA-DRB1. Fulfilment of this&#xD;
             criterion shall be considered sufficient evidence that the donor and recipient share&#xD;
             one HLA haplotype.&#xD;
&#xD;
          3. Age 16 to 65 years.&#xD;
&#xD;
          4. Normal estimated left ventricular ejection fraction ( &gt;30% ) and no history of&#xD;
             ischemic heart disease requiring revascularization, unless cleared by a cardiologist&#xD;
             (as per normal liver and bone marrow (BM) transplant eligibility requirements). Those&#xD;
             with an ejection fraction between 30-40%, will require a cardiology consultation and&#xD;
             clearance for transplantation.&#xD;
&#xD;
          5. Forced expiratory volume (FEV1) and forced vital capacity (FVC) &gt; 40% of predicted at&#xD;
             the screening visit.&#xD;
&#xD;
          6. Serum creatinine &lt;2.0 mg/dl&#xD;
&#xD;
          7. For women of childbearing potential, a negative serum or urine pregnancy test with&#xD;
             sensitivity less than 50 milli-International unit (mIU)/m within 72 hours before the&#xD;
             start of study medication.&#xD;
&#xD;
          8. Use of two forms of contraception with less than a 5% failure rate or abstinence by&#xD;
             all transplanted participants for 12 months after the first dose of study therapy. For&#xD;
             the first 60 days post-transplant, recipients should be encouraged to use non-hormonal&#xD;
             contraceptives due to the potential adverse effect of hormones on bone marrow&#xD;
             engraftment.&#xD;
&#xD;
          9. Ability to receive oral medication.&#xD;
&#xD;
         10. Ability to understand and provide informed consent.&#xD;
&#xD;
         11. Must meet all other criteria for listing for liver transplantation&#xD;
&#xD;
        DONOR:&#xD;
&#xD;
          1. HLA-matched or -haploidentical, parent, child, sibling, or half-sibling of the&#xD;
             recipient&#xD;
&#xD;
          2. Meets all requirements for live liver donation based on established criteria&#xD;
&#xD;
          3. Ability to understand and provide informed consent for all study procedures including&#xD;
             partial liver transplant and bone marrow harvest.&#xD;
&#xD;
          4. Age &lt; 60 years&#xD;
&#xD;
          5. Body Mass Index (BMI) &lt;35&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        RECIPIENT&#xD;
&#xD;
          1. Extrahepatic disease at the time of enrollment.&#xD;
&#xD;
          2. Macrovascular invasion by tumor as seen on imaging&#xD;
&#xD;
          3. Anti-donor HLA antibody with a level that produces a positive test on flow cytometric&#xD;
             crossmatch. [Note: patients with a positive flow cytometric crossmatch may undergo&#xD;
             desensitization and may become eligible, at the discretion of the protocol&#xD;
             investigators, if desensitization decreases the antibody concentration to a level that&#xD;
             produces a negative flow cytometric crossmatch.]&#xD;
&#xD;
          4. Ineligible for liver transplantation per institutional criteria (see Appendix 1)&#xD;
&#xD;
          5. Women who are breastfeeding.&#xD;
&#xD;
          6. History of positive HIV-1 or HIV-2 serologies or nucleic acid test.&#xD;
&#xD;
          7. Active hepatitis B infection as documented by positive Hepatitis B assay&#xD;
&#xD;
          8. Any active, severe local or systemic infection at the screening visit.&#xD;
&#xD;
          9. Use of investigational drug, other than the study medications specified by the&#xD;
             protocol, within 30 days of transplantation.&#xD;
&#xD;
         10. Receipt of a live vaccine within 30 days of receipt of study therapy.&#xD;
&#xD;
         11. The presence of any medical condition that the Investigator deems incompatible with&#xD;
             participation in the trial.&#xD;
&#xD;
        DONOR&#xD;
&#xD;
          1. Age: less than age 18 or older than age 60&#xD;
&#xD;
          2. BMI &gt;35&#xD;
&#xD;
          3. History of blood product donation to the recipient&#xD;
&#xD;
          4. Significant cardiovascular disease (per cardiology consultation)&#xD;
&#xD;
          5. Significant pulmonary disease (per pulmonology consultation)&#xD;
&#xD;
          6. Significant renal disease&#xD;
&#xD;
          7. History of diabetes mellitus&#xD;
&#xD;
          8. Ongoing malignancies&#xD;
&#xD;
          9. Severe local or systemic infection&#xD;
&#xD;
         10. Severe neurologic deficits&#xD;
&#xD;
         11. Active substance abuse&#xD;
&#xD;
         12. Untreatable/unstable psychiatric illness&#xD;
&#xD;
         13. History of positive HIV-1 or HIV-2 serology or nucleic acid test.&#xD;
&#xD;
         14. Evidence of prior hepatitis B infection as evaluated by hepatitis B surface antigen&#xD;
             (HBsAg), total hepatitis B core antibody, and hepatitis B surface antibody&#xD;
             (anti-HBsAb).&#xD;
&#xD;
         15. Positive HBV PCR&#xD;
&#xD;
         16. Positive anti-hepatitis C (HCV) antibodies and a positive serum HCV RNA PCR. All&#xD;
             positive HCV antibody results must be assessed by an electroimmunoassay enzyme-linked&#xD;
             immunosorbent assay (EIA) assay and confirmed by a quantitative serum HCV RNA assay.&#xD;
             Participants with positive HCV antibodies but undetectable serum HCV RNA may be&#xD;
             considered for eligibility. Participants with negative anti-HCV antibodies but&#xD;
             unexplained liver enzyme abnormalities must undergo a quantitative serum RNA assay to&#xD;
             rule out false negative HCV serologies.&#xD;
&#xD;
         17. Autoimmune disease requiring immunosuppressive drugs for maintenance.&#xD;
&#xD;
         18. The presence of any medical condition that the Investigator deems incompatible with&#xD;
             participation in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>February 26, 2016</study_first_submitted>
  <study_first_submitted_qc>March 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2016</study_first_posted>
  <last_update_submitted>June 13, 2018</last_update_submitted>
  <last_update_submitted_qc>June 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FL-HCC</keyword>
  <keyword>living donor liver transplant</keyword>
  <keyword>HLA matched first degree relative</keyword>
  <keyword>Milan Criteria</keyword>
  <keyword>Ephraim Fuchs</keyword>
  <keyword>Fibrolamellar Cancer Foundation</keyword>
  <keyword>fibrolamellar</keyword>
  <keyword>non-fibrolamellar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Mesna</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

